TOP TEN perturbations for 1552749_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552749_a_at
Selected probe(set): 239853_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552749_a_at (239853_at) across 6672 perturbations tested by GENEVESTIGATOR:

melanoma study 34 (metastatic) / melanoma study 34 (in situ)

Relative Expression (log2-ratio):-4.2537956
Number of Samples:40 / 2
Experimental melanoma study 34 (metastatic)
Metastatic tumor tissue sample obtained from the patients with metastatic malignant melanoma of the skin. Metastatic samples composed of 22 macroscopic lymph node metastases, 16 subcutaneous metastases and 2 solid organ metastases (adrenal and brain).
Control melanoma study 34 (in situ)
Tumor tissue from the skin of patients with melanoma in situ.

melanoma study 34 (metastatic) / normal skin tissue

Relative Expression (log2-ratio):-3.7835464
Number of Samples:40 / 4
Experimental melanoma study 34 (metastatic)
Metastatic tumor tissue sample obtained from the patients with metastatic malignant melanoma of the skin. Metastatic samples composed of 22 macroscopic lymph node metastases, 16 subcutaneous metastases and 2 solid organ metastases (adrenal and brain).
Control normal skin tissue
Normal skin tissue.

melanoma study 34 (primary) / melanoma study 34 (in situ)

Relative Expression (log2-ratio):-3.373478
Number of Samples:14 / 2
Experimental melanoma study 34 (primary)
Primary tumor tissue from the skin of patients with primary cutaneous melanoma (PCM). PCM consisted of 2 thin melanomas (< 1 mm; T1), 3 intermediate-thickness melanomas (1–4 mm; T2-3), and 9 thick melanomas (> 4 mm; T4).
Control melanoma study 34 (in situ)
Tumor tissue from the skin of patients with melanoma in situ.

Merkel cell carcinoma study 3 (metastatic) / normal skin tissue

Relative Expression (log2-ratio):-3.0219536
Number of Samples:11 / 64
Experimental Merkel cell carcinoma study 3 (metastatic)
Metastatic tumor tissue from different metastatic sites (skin, lymph node, parotid gland) of patients with Merkel cell carcinoma of the skin.
Control normal skin tissue
Normal skin samples from healthy donors.

Barrett's esophagus study 3 / esophageal squamous cell carcinoma study 1

Relative Expression (log2-ratio):-2.9862432
Number of Samples:17 / 8
Experimental Barrett's esophagus study 3
Esophageal epithelium samples from areas with Barrett's esophagus metaplasia which were recovered by laser capture microdissection.
Control esophageal squamous cell carcinoma study 1
Esophageal squamous cell carcinoma (ESCC) biopsy samples from chemotherapy-naive patients with histological grading G1 (well differentiated) and UICC stage II and III, which undergone esophagectomy.

Merkel cell carcinoma study 3 (primary) / normal skin tissue

Relative Expression (log2-ratio):-2.9786482
Number of Samples:19 / 64
Experimental Merkel cell carcinoma study 3 (primary)
Primary tumor tissue from the skin of patients with Merkel cell carcinoma.
Control normal skin tissue
Normal skin samples from healthy donors.

Barrett's esophagus study 3 / normal esophageal epithelium sample

Relative Expression (log2-ratio):-2.960867
Number of Samples:17 / 18
Experimental Barrett's esophagus study 3
Esophageal epithelium samples from areas with Barrett's esophagus metaplasia which were recovered by laser capture microdissection.
Control normal esophageal epithelium sample
Histologically normal esophageal squamous cell epithelium biopsy samples from patients that were investigated for esophageal pain, but diagnosed as healthy.

melanoma study 34 (primary) / normal skin tissue

Relative Expression (log2-ratio):-2.9032288
Number of Samples:14 / 4
Experimental melanoma study 34 (primary)
Primary tumor tissue from the skin of patients with primary cutaneous melanoma (PCM). PCM consisted of 2 thin melanomas (< 1 mm; T1), 3 intermediate-thickness melanomas (1–4 mm; T2-3), and 9 thick melanomas (> 4 mm; T4).
Control normal skin tissue
Normal skin tissue.

immunoglobulin (IVIG) study 1 (responder) / Kawasaki disease study 1

Relative Expression (log2-ratio):2.8173857
Number of Samples:6 / 4
Experimental immunoglobulin (IVIG) study 1 (responder)
Whole blood samples from subjects with Kawasaki disease treated with intravenous immunoglobulin therapy (IVIG; 2g/kg). The IVIG were infused over 24 hours as initial therapy between illness days 2 and 6 (median 5.5). The blood samples were obtained 36 hours after the end of intravenous application of immunoglobulins. Patients had good response to the therapy. ATC code:---
Control Kawasaki disease study 1
Whole blood samples from subjects with Kawasaki disease obtained prior to therapy between illness days 2 and 6 (median 5.5). The subjects showed later positive response to intravenous immunoglobulin therapy (IVIG; 2g/kg).

esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) / esophagus cancer study 1 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):2.798377
Number of Samples:3 / 8
Experimental esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted).
Control esophagus cancer study 1 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the oesophagus (subcutaneously implanted).